Rayaldee and Atrial fibrillation aggravated - a phase IV clinical study of FDA data

Summary:

Atrial fibrillation aggravated is reported only by a few people who take Rayaldee.

The phase IV clinical study analyzes which people take Rayaldee and have Atrial fibrillation aggravated. It is created by eHealthMe based on reports of 184 people who have side effects while taking Rayaldee from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 16, 2023

184 people reported to have side effects when taking Rayaldee.
Among them, 3 people (1.63%) have Atrial fibrillation aggravated.

What is Rayaldee?

Rayaldee has active ingredients of calcifediol. eHealthMe is studying from 186 Rayaldee users for its effectiveness, alternative drugs and more.

What is Atrial fibrillation aggravated?

Atrial fibrillation aggravated (serious fibrillation of the muscles of the atria of the heart) is found to be associated with 2,165 drugs and 835 conditions by eHealthMe.

Number of Rayaldee and Atrial fibrillation aggravated reports submitted per year:

Could Rayaldee cause Atrial fibrillation aggravated?

Gender of people who have Atrial fibrillation aggravated when taking Rayaldee *:

female: 100 %
male: 0.0 %

Age of people who have Atrial fibrillation aggravated when taking Rayaldee *:

Common drugs people take besides Rayaldee *:

Uloric: 2 people, 66.67%
Potassium: 2 people, 66.67%
Crestor: 2 people, 66.67%
Amlodipine: 2 people, 66.67%
Eliquis: 1 person, 33.33%

Common side effects people have besides Atrial fibrillation aggravated *:

Stress And Anxiety: 2 people, 66.67%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 2 people, 66.67%
Gout (uric acid crystals building up in the body): 2 people, 66.67%
Dry Eyes (lack of adequate tears): 2 people, 66.67%
Breathing Difficulty: 2 people, 66.67%
Back Pain: 2 people, 66.67%
Weakness: 1 person, 33.33%
Blood Parathyroid Hormone Decreased: 1 person, 33.33%
Blood Calcium Decreased: 1 person, 33.33%

Common conditions people have *:

Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 66.67%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 66.67%
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Rayaldee and have Atrial fibrillation aggravated?

Check whether Atrial fibrillation aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Atrial fibrillation aggravated and when was it recovered:

Atrial fibrillation aggravated in Rayaldee

Expand to all the drugs that have ingredients of calcifediol:

Atrial fibrillation aggravated and drugs with ingredients of calcifediol

Alternative drugs to, pros and cons of Rayaldee:

Rayaldee (186 reports)

Atrial fibrillation aggravated treatments and more:

Atrial fibrillation aggravated (654 reports)

COVID vaccines that are related to Atrial fibrillation aggravated:

Common drugs associated with Atrial fibrillation aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on calcifediol (the active ingredients of Rayaldee) and Rayaldee (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.